688192 迪哲医药
已收盘 07-25 15:00:01
资讯
新帖
简况
差价600亿，这款国产药贱卖了？
中国新闻周刊 · 07-24 23:01
差价600亿，这款国产药贱卖了？
迪哲医药：7月23日高管HONCHUNG TSUI(徐汉忠)、陈素勤减持股份合计4.25万股
证券之星 · 07-24 12:02
迪哲医药：7月23日高管HONCHUNG TSUI(徐汉忠)、陈素勤减持股份合计4.25万股
肿瘤治疗概念盘中拉升，键凯科技涨12.91%
市场透视 · 07-24 01:47
肿瘤治疗概念盘中拉升，键凯科技涨12.91%
迪哲医药：多位股东减持股份
南方财经网 · 07-23 11:26
迪哲医药：多位股东减持股份
迪哲医药(688192.SH)：舒沃哲®和高瑞哲®多项研究成果入选2025年世界肺癌大会
智通财经 · 07-23 11:15
迪哲医药(688192.SH)：舒沃哲®和高瑞哲®多项研究成果入选2025年世界肺癌大会
券商资管系公募，排名来了！
中国基金报 · 07-22
券商资管系公募，排名来了！
每周股票复盘：迪哲医药（688192）发生2笔大宗交易成交406.02万元
证券之星 · 07-19
每周股票复盘：迪哲医药（688192）发生2笔大宗交易成交406.02万元
高管减持迪哲医药另一面：全球化战略会是下个百济神州吗？【医药视界】
投资者网 · 07-16
高管减持迪哲医药另一面：全球化战略会是下个百济神州吗？【医药视界】
迪哲医药 -U主力两日净流出1517.4万 资金谨慎股价或承压
智选洞察 · 07-16
迪哲医药 -U主力两日净流出1517.4万 资金谨慎股价或承压
科创成长层改革推进 券商系统升级及风险揭示书签署有序展开
DoNews · 07-16
科创成长层改革推进 券商系统升级及风险揭示书签署有序展开
医药主题基金首批二季报出炉！这只产品规模环比增30倍
北京商报官方账号 · 07-14
医药主题基金首批二季报出炉！这只产品规模环比增30倍
7月14日迪哲医药发生2笔大宗交易 成交金额406.02万元
证券之星 · 07-14
7月14日迪哲医药发生2笔大宗交易 成交金额406.02万元
舒沃哲纳入美国国立综合癌症网络（NCCN）指南
环球网 · 07-14
舒沃哲纳入美国国立综合癌症网络（NCCN）指南
每周股票复盘：迪哲医药（688192）高管减持及机构大额净买入
证券之星 · 07-12
每周股票复盘：迪哲医药（688192）高管减持及机构大额净买入
迪哲医药高级管理人员吴清漪减持计划完成，套现超1900万元
中访网数据 · 07-09
迪哲医药高级管理人员吴清漪减持计划完成，套现超1900万元
迪哲医药7月8日现6笔大宗交易 总成交金额5088.5万元 其中机构买入4718.55万元 溢价率为-8.00%
新浪证券-红岸工作室 · 07-08
迪哲医药7月8日现6笔大宗交易 总成交金额5088.5万元 其中机构买入4718.55万元 溢价率为-8.00%
迪哲医药舒沃哲获FDA加速批准上市，全球首款在美获批的 EGFR exon20ins肺癌国创新药诞生
药智网 · 07-08
迪哲医药舒沃哲获FDA加速批准上市，全球首款在美获批的 EGFR exon20ins肺癌国创新药诞生
迪哲医药：副总经理张世英减持不超过0.0035%股份
公司公告 · 07-07
迪哲医药：副总经理张世英减持不超过0.0035%股份
7月7日迪哲医药现845.32万元大宗交易
证券之星 · 07-07
7月7日迪哲医药现845.32万元大宗交易
本月，4款创新药有望获FDA批准上市！涉及黑色素瘤、湿疹等适应症
制药网 · 07-07
本月，4款创新药有望获FDA批准上市！涉及黑色素瘤、湿疹等适应症
加载更多
公司概况
公司名称：
迪哲(江苏)医药股份有限公司
所属行业：
医药制造业
上市日期：
2021-12-10
主营业务：
迪哲(江苏)医药股份有限公司的主营业务是公司是一家创新型生物医药企业，专注于恶性肿瘤、免疫性疾病领域创新疗法的研究、开发和商业化。公司的主要产品是抗肿瘤药物。
发行价格：
52.58
{"stockData":{"symbol":"688192","market":"SH","secType":"STK","nameCN":"迪哲医药","latestPrice":72.47,"timestamp":1753426801000,"preClose":74.1,"halted":0,"volume":3845731,"delay":0,"changeRate":-0.022,"floatShares":409999999,"shares":459000000,"eps":-1.7724,"marketStatus":"已收盘","change":-1.63,"latestTime":"07-25 15:00:01","open":74.02,"high":76.22,"low":71.61,"amount":281000000,"amplitude":0.0622,"askPrice":72.47,"askSize":48,"bidPrice":72.45,"bidSize":9,"shortable":0,"etf":0,"ttmEps":-1.7724,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1753666200000},"marketStatusCode":5,"adr":0,"adjPreClose":74.1,"symbolType":"stock_kcb","openAndCloseTimeList":[[1753407000000,1753414200000],[1753419600000,1753426800000]],"highLimit":81.51,"lowLimit":66.69,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":459412894,"isCdr":false,"pbRate":1803.52,"roa":"--","roe":"--","epsLYR":-2.04,"committee":-0.44,"marketValue":33294000000,"turnoverRate":0.0094,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2025-07-28。","afterMarket":{"amount":0,"volume":0,"close":72.47,"buyVolume":0,"sellVolume":0,"time":1753428838020,"indexStatus":"已收盘 07-25 15:30:00","preClose":74.1},"floatMarketCap":29693000000},"requestUrl":"/m/hq/s/688192","defaultTab":"news","newsList":[{"id":"2554364567","title":"差价600亿，这款国产药贱卖了？","url":"https://stock-news.laohu8.com/highlight/detail?id=2554364567","media":"中国新闻周刊","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554364567?lang=zh_cn&edition=full","pubTime":"2025-07-25 07:01","pubTimestamp":1753398093,"startTime":"0","endTime":"0","summary":"2023年10月16日，在2023上海国际生物医药产业周开幕活动中举行的上海市创新药械出海国际合作伙伴计划启航仪式。5月底，三生制药与跨国药企辉瑞达成一项合作，12.5亿美元的首付款刷新了国内创新药海外授权的首付款纪录，大大调动起了二级市场的热情。截至7月16日，恒生港股通创新药精选指数累计上涨近80％。截至目前，和铂医药已完成17次BD出海交易。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725071241a6c0592c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725071241a6c0592c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01093","688192","01276","BK0239","02142","688506","01530"],"gpt_icon":0},{"id":"2553200989","title":"迪哲医药：7月23日高管HONCHUNG TSUI(徐汉忠)、陈素勤减持股份合计4.25万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2553200989","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553200989?lang=zh_cn&edition=full","pubTime":"2025-07-24 20:02","pubTimestamp":1753358538,"startTime":"0","endTime":"0","summary":"证券之星消息，根据7月24日市场公开信息、上市公司公告及交易所披露数据整理，迪哲医药最新董监高及相关人员股份变动情况：2025年7月23日公司高级管理人员,核心技术人员HONCHUNG TSUI(徐汉忠)、高级管理人员,核心技术人员陈素勤共减持公司股份4.25万股，占公司总股本为0.0092%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072400033574.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688192"],"gpt_icon":0},{"id":"2553227537","title":"肿瘤治疗概念盘中拉升，键凯科技涨12.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2553227537","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553227537?lang=zh_cn&edition=full","pubTime":"2025-07-24 09:47","pubTimestamp":1753321645,"startTime":"0","endTime":"0","summary":"07月24日，肿瘤治疗概念盘中拉升，截至09点47分，肿瘤治疗概念整体指数上涨1.03%，报1676.640点。从个股上来看，该概念的成分股中，键凯科技涨12.91%，沃森生物、迪哲医药-U2只股涨幅超过5%。从资金上来看，截止发稿，肿瘤治疗概念主力净流入为-1.77亿，其中恒瑞医药受到资金热捧，主力净流入4686.57万；拉长时间线来看，该板块近20日主力资金净流入-39.86亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724094725971aef26&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724094725971aef26&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688356","BK0229","688192"],"gpt_icon":0},{"id":"2553501210","title":"迪哲医药：多位股东减持股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2553501210","media":"南方财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553501210?lang=zh_cn&edition=full","pubTime":"2025-07-23 19:26","pubTimestamp":1753269960,"startTime":"0","endTime":"0","summary":"南财智讯7月23日电，迪哲医药公告，杨振帆、陈素勤、QingbeiZeng、HonchungTsui及吕洪斌因个人资金需求，于2025年6月26日披露了减持股份计划，计划通过集中竞价方式减持各自持有的部分公司股份。截至2025年7月23日，所有高级管理人员均已完成其各自的减持计划，减持价格区间在65.47至71.24元/股之间，减持总金额合计超过1亿元人民币。（文章来源：南方财经网）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723193228954e9dbb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723193228954e9dbb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688192"],"gpt_icon":0},{"id":"2553212454","title":"迪哲医药(688192.SH)：舒沃哲®和高瑞哲®多项研究成果入选2025年世界肺癌大会","url":"https://stock-news.laohu8.com/highlight/detail?id=2553212454","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553212454?lang=zh_cn&edition=full","pubTime":"2025-07-23 19:15","pubTimestamp":1753269316,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迪哲医药(688192.SH)发布公告，公司将在2025年9月6日至9日于西班牙巴塞罗那举行的2025年世界肺癌大会(WCLC)上，公布其自主研发的新型肺癌靶向药舒沃哲®(ZEGFROVY®，通用名：舒沃替尼片)和高选择性JAK1抑制剂高瑞哲®(通用名：戈利昔替尼胶囊)在非小细胞肺癌中的多项最新研究成果。其中，舒沃哲®国际多中心注册临床研究“悟空1B”(WU-KONG1B)最新数据入选口头报告。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1321140.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"迪哲医药(688192.SH)：舒沃哲®和高瑞哲®多项研究成果入选2025年世界肺癌大会","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688192"],"gpt_icon":0},{"id":"2553575942","title":"券商资管系公募，排名来了！","url":"https://stock-news.laohu8.com/highlight/detail?id=2553575942","media":"中国基金报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553575942?lang=zh_cn&edition=full","pubTime":"2025-07-23 00:06","pubTimestamp":1753200372,"startTime":"0","endTime":"0","summary":"头部券商资管公募管理规模普遍增长Wind数据显示，截至二季度末，共有4家券商资管机构的公募基金资产管理总规模超千亿元。此外，相比于今年一季度末，头部券商资管的公募管理规模普遍增长，东方红资产管理、华泰证券资管规模增长均超200亿元，招商证券资管规模增长33亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723001401a45cdc20&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723001401a45cdc20&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06990","01276","688235","BK0239","09969","ONC","688428","600276","688192","06160","688266","688443"],"gpt_icon":0},{"id":"2552412237","title":"每周股票复盘：迪哲医药（688192）发生2笔大宗交易成交406.02万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2552412237","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552412237?lang=zh_cn&edition=full","pubTime":"2025-07-20 01:56","pubTimestamp":1752947768,"startTime":"0","endTime":"0","summary":"截至2025年7月18日收盘，迪哲医药（688192）报收于67.95元，较上周的63.8元上涨6.5%。本周，迪哲医药7月18日盘中最高价报68.18元。7月14日盘中最低价报63.58元。迪哲医药当前最新总市值312.17亿元，在化学制药板块市值排名18/150，在两市A股市值排名499/5149。本周关注点交易信息汇总: 7月14日迪哲医药发生2笔大宗交易，成交金额406.02万元交易信息汇总7月14日迪哲医药发生2笔大宗交易，成交金额406.02万元。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072000000471.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688192"],"gpt_icon":0},{"id":"2551576142","title":"高管减持迪哲医药另一面：全球化战略会是下个百济神州吗？【医药视界】","url":"https://stock-news.laohu8.com/highlight/detail?id=2551576142","media":"投资者网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551576142?lang=zh_cn&edition=full","pubTime":"2025-07-16 18:01","pubTimestamp":1752660075,"startTime":"0","endTime":"0","summary":"减持释放什么信号迪哲医药进入一个高层减持密集期。其中，吴清漪减持金额超1900万元，股份来源于股权激励及二级市场增持。截至目前，公司仍无控股股东、实际控制人。获批上市后，该药被成功纳入医保。公司表示，两款药品纳入医保目录后，销量大幅增加。最为市场熟知的，是百济神州的泽布替尼。受此因素，该药成功在欧美获批上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716180622a6ad36ff&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716180622a6ad36ff&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","BK4526","ONC","BK4139","688192","06160"],"gpt_icon":0},{"id":"2551465281","title":"迪哲医药 -U主力两日净流出1517.4万 资金谨慎股价或承压","url":"https://stock-news.laohu8.com/highlight/detail?id=2551465281","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551465281?lang=zh_cn&edition=full","pubTime":"2025-07-16 16:08","pubTimestamp":1752653306,"startTime":"0","endTime":"0","summary":"迪哲医药-U今日主力资金净流出544.1万元，上一交易日主力资金净流出97.3万元。资金面与政策预期共振引发短期波动近期迪哲医药-U主力资金呈现多空博弈特征，截至7月15日，其单日主力资金净流出97.3万元，而前一交易日曾获323万元净流入。研发管线兑现度构筑长期估值锚点迪哲医药-U长期逻辑取决于临床管线的商业化兑现能力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716164602a6ad064a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716164602a6ad064a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688192"],"gpt_icon":0},{"id":"2551119280","title":"科创成长层改革推进 券商系统升级及风险揭示书签署有序展开","url":"https://stock-news.laohu8.com/highlight/detail?id=2551119280","media":"DoNews","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551119280?lang=zh_cn&edition=full","pubTime":"2025-07-16 11:13","pubTimestamp":1752635582,"startTime":"0","endTime":"0","summary":"上交所方面正组织风险揭示书签署工作，并修订相关指南，新增《科创板科创成长层企业股票投资风险揭示书必备条款》，明确未盈利企业存在的各类投资风险。上交所下发通知要求券商完善适当性管理工作，包括完成风险揭示书签署及系统准备，给予投资者充分阅读时间，并通过多种渠道开展投资者教育。上交所将持续督促券商并开展监督检查。7月14日，上交所举办专题培训会，120家券商330余名相关负责人参会。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071611164495444cb2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071611164495444cb2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688327","688343","688221","688322","688176","688382","688192","688302","01877","688373","06160","688197","02402","688220","688316","688266","688702","688512","BK0239","688165","000690.SH","688280","688538","09969","688549","688515","688277","688561","688256","688469","ONC","688443","688387"],"gpt_icon":0},{"id":"2551188325","title":"医药主题基金首批二季报出炉！这只产品规模环比增30倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2551188325","media":"北京商报官方账号","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551188325?lang=zh_cn&edition=full","pubTime":"2025-07-14 18:40","pubTimestamp":1752489611,"startTime":"0","endTime":"0","summary":"公募基金二季报陆续披露中。就在前几日，长城基金也披露了旗下4只医药主题基金二季报。从规模变动来看，5只医药主题基金环比均有不同幅度的增长，其中长城医药产业精选混合型发起式的最新规模更大涨超30倍。公开资料显示，截至7月14日，已有永赢医药健康股票、长城医药产业精选混合型发起式、长城医药科技六个月持有期混合、长城医疗保健混合、长城大健康混合合计5只医药健康相关主题基金发布2025年二季报。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714184621a6a89973&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714184621a6a89973&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688520","688382","688068","688192","000121.SH","688331","603590","BK0239"],"gpt_icon":0},{"id":"2551901431","title":"7月14日迪哲医药发生2笔大宗交易 成交金额406.02万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2551901431","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551901431?lang=zh_cn&edition=full","pubTime":"2025-07-14 17:20","pubTimestamp":1752484844,"startTime":"0","endTime":"0","summary":"证券之星消息，7月14日迪哲医药发生大宗交易，交易数据如下：近三个月该股共发生17笔大宗交易，合计成交1.4万手，折价成交17笔。该股在过去半年内已有共计2.23亿股限售解禁股上市，占公司总股本的48.54%。截至2025年7月14日收盘，迪哲医药(688192)报收于64.9元，上涨1.72%，换手率0.72%，成交量2.97万手，成交额1.92亿元。该股最近90天内共有12家机构给出评级，买入评级10家，增持评级2家；过去90天内机构目标均价为80.75。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071400024805.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688192"],"gpt_icon":0},{"id":"2551183325","title":"舒沃哲纳入美国国立综合癌症网络（NCCN）指南","url":"https://stock-news.laohu8.com/highlight/detail?id=2551183325","media":"环球网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551183325?lang=zh_cn&edition=full","pubTime":"2025-07-14 14:31","pubTimestamp":1752474668,"startTime":"0","endTime":"0","summary":"日前，迪哲医药舒沃哲被纳入美国国立综合癌症网络非小细胞肺癌指南推荐，用于治疗经治表皮生长因子受体20号外显子插入突变非小细胞肺癌，成为全球唯一纳入国际权威肺癌指南的EGFR exon20ins NSCLC小分子靶向药。该药物已于7月3日通过优先审评获美国食品药品监督管理局批准上市，成为全球首个且唯一在美国获批的EGFR exon20ins NSCLC国创新药，也是中国首个独立研发在美获批的全球首创新药。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714143331a449200b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714143331a449200b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688192"],"gpt_icon":0},{"id":"2551919584","title":"每周股票复盘：迪哲医药（688192）高管减持及机构大额净买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2551919584","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551919584?lang=zh_cn&edition=full","pubTime":"2025-07-13 03:34","pubTimestamp":1752348849,"startTime":"0","endTime":"0","summary":"截至2025年7月11日收盘，迪哲医药报收于63.8元，较上周的65.8元下跌3.04%。本周，迪哲医药7月7日盘中最高价报69.45元，股价触及近一年最高点。股本股东变化2025年7月7日，公司高级管理人员吴清漪共减持公司股份6.81万股，占公司总股本的0.0148%。吴清漪女士截至2025年7月7日收盘，通过集中竞价累计减持了公司股份302054股，占公司总股本0.0657%，减持总金额为19013369.89元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071300000620.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688192"],"gpt_icon":0},{"id":"2550574343","title":"迪哲医药高级管理人员吴清漪减持计划完成，套现超1900万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2550574343","media":"中访网数据","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550574343?lang=zh_cn&edition=full","pubTime":"2025-07-09 08:04","pubTimestamp":1752019451,"startTime":"0","endTime":"0","summary":"中访网数据 迪哲(江苏)医药股份有限公司近日发布公告，公司首席商务官、副总经理吴清漪女士的股份减持计划已实施完毕。但吴清漪实际减持时间为2025年6月27日至7月7日，提前完成减持。减持完成后，吴清漪仍持有公司股份906,163股，占总股本的0.1972%。公告显示，吴清漪减持的股份来源包括股权激励计划归属及二级市场增持。迪哲医药表示，本次减持不会对公司治理结构及持续经营产生重大影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709081313979ef5da&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709081313979ef5da&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688192","BK0239"],"gpt_icon":0},{"id":"2549654385","title":"迪哲医药7月8日现6笔大宗交易 总成交金额5088.5万元 其中机构买入4718.55万元 溢价率为-8.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2549654385","media":"新浪证券-红岸工作室","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549654385?lang=zh_cn&edition=full","pubTime":"2025-07-08 17:40","pubTimestamp":1751967600,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 7月8日，迪哲医药收涨0.23%，收盘价为64.86元，发生6笔大宗交易，合计成交量85.28万股，成交金额5088.5万元。 第2笔成交价格为59.67元，成交30.30万股，成交金额1,808.00万元，溢价率为-8.00%，买方营业部为机构专用，卖方营业部为中国国际金融股份有限公司上海分公司。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/ggzz/2025-07-08/doc-infeufem5704695.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","688192"],"gpt_icon":0},{"id":"2549411596","title":"迪哲医药舒沃哲获FDA加速批准上市，全球首款在美获批的 EGFR exon20ins肺癌国创新药诞生","url":"https://stock-news.laohu8.com/highlight/detail?id=2549411596","media":"药智网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549411596?lang=zh_cn&edition=full","pubTime":"2025-07-08 11:37","pubTimestamp":1751945825,"startTime":"0","endTime":"0","summary":"舒沃哲通过优先审评程序获得批准上市，成为目前全球首个且唯一在美获批的EGFR exon20ins NSCLC国创新药。近年来，全球范围内针对EGFR exon20insNSCLC研发的新药大多以失败告终。迪哲医药首创独特分子结构设计，从源头突破这一难治靶点，并以国际多中心临床试验证实了舒沃替尼在EGFR exon20ins NSCLC治疗的突破性价值。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708114126a43d1830&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708114126a43d1830&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","159992","688192"],"gpt_icon":0},{"id":"2549558190","title":"迪哲医药：副总经理张世英减持不超过0.0035%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2549558190","media":"公司公告","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549558190?lang=zh_cn&edition=full","pubTime":"2025-07-07 21:07","pubTimestamp":1751893645,"startTime":"0","endTime":"0","summary":"迪哲医药公告，副总经理张世英于2025年6月25日至2025年7月4日以集中竞价方式减持股份1.616万股，占总股本的0.0035%，减持计划已实施完毕。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707211904a69b14cb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707211904a69b14cb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688192"],"gpt_icon":0},{"id":"2549458037","title":"7月7日迪哲医药现845.32万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2549458037","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549458037?lang=zh_cn&edition=full","pubTime":"2025-07-07 17:20","pubTimestamp":1751880041,"startTime":"0","endTime":"0","summary":"证券之星消息，7月7日迪哲医药发生大宗交易，交易数据如下：近三个月该股共发生4笔大宗交易，合计成交1420.0手，折价成交4笔。该股在过去半年内已有共计2.23亿股限售解禁股上市，占公司总股本的48.54%。截至2025年7月7日收盘，迪哲医药(688192)报收于64.71元，下跌1.66%，换手率1.37%，成交量5.63万手，成交额3.73亿元。该股最近90天内共有11家机构给出评级，买入评级10家，增持评级1家；过去90天内机构目标均价为74.89。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070700023180.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688192"],"gpt_icon":0},{"id":"2549305651","title":"本月，4款创新药有望获FDA批准上市！涉及黑色素瘤、湿疹等适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=2549305651","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549305651?lang=zh_cn&edition=full","pubTime":"2025-07-07 10:14","pubTimestamp":1751854475,"startTime":"0","endTime":"0","summary":"而截至2025年7月5日，已有2款新药已获得FDA批准上市，分别为迪哲医药的舒沃替尼片和再生元的双特异性抗体Lynozyfic 。除以上两个创新药外，7月有望获得FDA批准上市的创新药包括Replimune Group的RP1、LEO Pharma的Delgocitinib、PTC Therapeutics的Sepiapterin、再生元的Odronextamab。期待更多创新药物能够顺利获批上市，为更多疾病的治疗带来变革。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507071015289538ff0d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507071015289538ff0d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688192","159992","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1753505172541,"stockEarnings":[{"period":"1week","weight":0.0665},{"period":"1month","weight":0.1861},{"period":"3month","weight":0.2804},{"period":"6month","weight":0.7416},{"period":"1year","weight":0.9382},{"period":"ytd","weight":0.7475}],"compareEarnings":[{"period":"1week","weight":0.0167},{"period":"1month","weight":0.0398},{"period":"3month","weight":0.0906},{"period":"6month","weight":0.1048},{"period":"1year","weight":0.2449},{"period":"ytd","weight":0.0722}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"迪哲(江苏)医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"8686人(较上一季度增加2.65%)","perCapita":"47171股","listingDate":"2021-12-10","address":"江苏省无锡市新吴区和风路26号汇融商务广场C栋404、405、416室","registeredCapital":"45941万元","survey":" 迪哲(江苏)医药股份有限公司的主营业务是公司是一家创新型生物医药企业，专注于恶性肿瘤、免疫性疾病领域创新疗法的研究、开发和商业化。公司的主要产品是抗肿瘤药物。","listedPrice":52.58},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.4","shortVersion":"4.34.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"迪哲医药(688192)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供迪哲医药(688192)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"迪哲医药,688192,迪哲医药股票,迪哲医药股票老虎,迪哲医药股票老虎国际,迪哲医药行情,迪哲医药股票行情,迪哲医药股价,迪哲医药股市,迪哲医药股票价格,迪哲医药股票交易,迪哲医药股票购买,迪哲医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"迪哲医药(688192)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供迪哲医药(688192)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}